169679-45-2

Upstream product

• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 167403-92-1 4-tert-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenyl)thio-4-pyrimidinyl)benzenesulfonamide 
• 15084-51-2 4-tert-butylbenzenesulfonyl chloride 
• 167403-91-0 4-tert-butyl-N-(6-chloro-5-(2-methoxyphenyl)thio-4-pyrimidinyl)benzenesulfonamide 
• 374600-17-6 4,6-dichloro-5-(2-methoxyphenyl)thiopyrimidine 
• 6292-59-7 4-tert-butylbenzenesulphonamide 
• 71556-63-3 o-methoxybenzenesulfenyl chloride 
• 13920-94-0 bis(2-methoxyphenyl)disulfide 
• 167403-89-6 5-(2-methoxyphenyl)thiopyrimidine-4,6-diol 

Relevant academic research and scientific papers

Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives

Modifications to the ETA/B mixed type compounds 1 (Ro. 46-2005) and 2 (bosentan) were performed. Introduction of a pyrimidine group into 1 resulted in a dramatic increase in affinity for the ETA receptor, and the subsequent optimization of substituents on the pyrimidine ring led us to the discovery of N-(6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-5-(4-methylphenyl)- 4pyrimidinyl)-4-tert-butylbenzenesulfonamide (7k), which showed an extremely high affinity for the human cloned ETA receptor (Ki=0.0042±0.0038 nM) and an ETA/B receptor selectivity up to 29 000 (Ki=130±50 nM for the human cloned ETB receptor). The compound was designed on the hypothesis that the hydrogen atom of the hydroxyl group in 1 and 2 played a role not as a proton donor but as an acceptor in the possible hydrogen bonding with Tyr129. Since the incorporation of a pyrimidinyl group into the hydroxyethoxy side chain of the nonselective antagonist (1) dramatically enhanced both the ETA receptor affinity and selectivity, and since similar results were obtained from the benzene analogues, we put forward the hypothesis that a "pyrimidine binding pocket" might exist in the ETA receptor.